Ultrasound and shear-wave elastography patterns of COVID-19 mRNA vaccine-related axillary, supra and subclavicular lymphadenopathy

Divina D’Auria1 · Ludovica Fulgione1 · Valeria Romeo1 · Arnaldo Stanzione1 · Simone Maurea1 · Arturo Brunetti1

Received: 21 May 2021 / Accepted: 9 June 2021 / Published online: 18 June 2021 © The Author(s) 2021

Abstract
In this pictorial essay, we illustrate the ultrasound appearance of COVID-19 Pfizer-BioNTech vaccine-related lymph node abnormalities, which can occur at different stations ipsilateral to the site of vaccination, after either first or second vaccine dose and can represent a diagnostic dilemma when encountered in patients with underlying conditions. Typically, they appear as enlarged hypoechoic nodes with loss of fat hilum, increased hilar and cortical vascularization at color-Doppler, but low to intermediate cortical consistence at shear-wave elastography. Asymmetric or diffuse cortical thickening is also frequently encountered. They can be observed in patients without and with clinical symptoms, such as armpit pain, fever and fatigue.

Keywords Covid-19 · Lymphadenopathy · Ultrasound · Shear-wave elastography · Vaccine · mRNA vaccine

Introduction
Achieving herd immunity through a mass vaccination campaign currently represents the most promising strategy in the pursuit of an end to the global crisis related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, as demonstrated in Israel by the recent results achieved with the BNT162b2 mRNA (Pfizer-BioNTech) vaccine for coronavirus disease 2019 (COVID-19) [1]. This encouraging evidence confirms the clinical trials findings which had also revealed a reassuring safety profile of the Pfizer-BioNTech vaccine, with mostly minor and transient side effects reported [2]. Among these, ipsilateral vaccine-related lymphadenopathy is expected to become a common incidental imaging finding to be dealt with, while the data regarding their number, size, sites, morphology and imaging features are still scarce [3]. In oncologic patients, these abnormal findings might be mistaken for metastases and a recent history of COVID-19 vaccine can provide relevant information to guide the differential diagnosis of enlarged lymph nodes [4, 5]. Ultrasound (US) is a widespread and extensively used imaging techniques and particularly the first-choice modality for lymph nodes assessment. We, therefore, aim to provide an overview of the most relevant US findings of COVID-19 vaccine encountered in health worker subjects, including B-mode, color-Doppler and shear-wave elastography of both axillary and supra/subclavicular lymph nodes, also trying to define a temporal evolution of detected lymphadenopathies trough a 1-month follow-up assessment.

Cases presentation
US examinations were performed in young healthcare professionals, with no previous pathological conditions, between February and March 2021 during the Italian vaccination campaign, who presented at our Radiology Department after receiving Pfizer-BioNTech vaccine. US were performed using a GE Logiq S8 scanner equipped with a high-frequency linear probe (11–15 MHz). Bilateral axillary, supraclavicular, sub-clavicular and cervical lymph node stations were explored. A first B-mode evaluation was performed with measurement of long/short lymph node axis as well as cortical thickness. Lymph node shape, margins and fatty hilum were also evaluated. The examination was completed with color-Doppler assessment of hilar/cortical vascularization and quantitative shear-wave elastography.
measurement of thickened cortex. In female subjects, breast US was also performed to rule out the presence of suspected/pathological breast lesions that could explain the occurrence of ipsilateral lymphadenopathies.

All subjects gave their written informed consent for the use of both imaging and clinical data for research purposes.

Case 1

A 28-year-old female subject underwent US examination 2 days after receiving the second dose of Pfizer-BioNTech vaccine due to palpable left axillary lump and ipsilateral armpit pain (same side of vaccine injection). She also experienced fatigue and headache. US showed the presence of axillary lymph nodes (maximum diameter 14 × 9 mm) with preserved fatty hilum, but diffuse cortical thickening (10 mm) and vivid hilar and cortical vascularization. A soft consistence of the cortex was found at shear-wave elastography (mean values between 3.4 and 8.1 kPa). No pathological lymph nodes were found in ipsilateral supra and subclavicular lymph node stations as well as in lymph nodes contralateral to the site of vaccine injection. Follow-up US examination was performed after 4 weeks and a reduction of lymph node size (7 × 6 mm), cortical thickness (2.9 mm) and vascularization was found (Fig. 1).

Case 2

A 28-year-old woman, who experienced headache and left axillary pain after the second vaccine dose, performed a US examination 2 days after that revealed the presence of enlarged (26 × 7 mm) axillary lymph nodes with preserved fatty hilum, thickened cortex (5 mm) and increased vascularization at color-Doppler. A pathological ipsilateral subclavicular lymph node (33 × 11 mm) was also found with no visible fatty hilum and increased vascular signal (Fig. 2). In both nodes, shear-wave elastography showed a soft texture (mean values between 13 and 18 kPa). No pathological lymph nodes were found in lymph node stations contralateral to the site of vaccine injection. The patient had previously undergone a breast US for a routine control after receiving the first vaccine dose, that did not show any significant abnormalities.

Case 3

A 29-year-old female subject underwent US examination 3 days after receiving the second dose of Pfizer-BioNTech vaccine, due to the rapid occurrence of a palpable lump at the level of the left axilla (same site of vaccine injection), along with fatigue. Multiple, round, hypoechoic axillary...
lymph nodes (maximum diameter 11 × 10 mm) with no fatty hilum and mild hilar vascularization. Shear-wave elastography revealed a soft consistence (mean values between 6 and 19 kPa). Follow-up US examination performed 5 weeks after the second dose only showed a reduction in lymph node size (maximum diameter 9 × 6 mm) (Fig. 3). No pathological lymph nodes were found in both ipsilateral and contralateral supra/subclavicular and cervical stations as well as in the contralateral axilla.

Case 4

A 28-year-old male asymptomatic subject underwent US examination for screening purpose 3 days after the second vaccine dose. A round hypoechoic axillary lymph node (13 × 20 mm) was found with increased vascular signal at color-Doppler examination at the same site of vaccine injection (left arm). An enlarged axillary lymph node was also detected (21 × 7 mm) with preserved hilar representation but diffuse cortical thickening (6 mm) and abnormal vascularization. Both lymph nodes showed soft consistence at shear-wave sonoelastography (mean values between 27 and 38 kPa). No pathological lymph nodes were found in both ipsilateral and contralateral supra/subclavicular and cervical stations as well as in the contralateral axilla. Both findings were no longer detectable at 4 weeks US examination (Fig. 4).

Case 5

US examination was performed in a 33-year-old woman with the occurrence of axillary pain and a palpable lump in the supraclavicular region 8 days after the first dose of Pfizer-BioNTech vaccine. The patient had also experienced fever and fatigue right after vaccine injection. Both axillary and supraclavicular lymph nodes were found enlarged (maximum diameter 14 × 6 mm), with no fatty hilum, increased vascularization and soft-intermediate consistence at shear-wave sonoelastography (Fig. 5). No pathological lymph nodes were found in the contralateral axilla. US lymph node features were substantially stable at US examinations performed after 3 weeks.

Case 6

A 30-year-old woman with the onset of fever, myalgia and left armpit pain ipsilateral to vaccine injection after the first dose underwent US examination 5 days later.
Fig. 3 B-Mode (A) and color-Doppler (B) US examination performed 3 days after receiving the second vaccine dose. Multiple round (maximum diameter 11 × 10 mm) axillary lymph nodes with no fatty hilum and mild hilar vascularization were detected. B-Mode (C, D) and color-Doppler (E) US examination performed after 5 weeks. Only a reduction of lymph node size (maximum diameter 9 × 6 mm) was detectable.

Fig. 4 B-Mode (A, C) and color-Doppler (B, D) US examination performed 3 days after receiving the second dose of vaccine. Enlarged (maximum diameter 21 × 7 mm) axillary lymph node with preserved fatty hilum (* in A and C), diffuse cortical thickening (6 mm, arrows in A and C) and vivid hilar and cortical vascularization (B, D) were found.
Multiple axillary lymphadenopathies (maximum diameter 15 × 10 mm) with round to oval shape, poor hilar representation, thickened cortex and increased vascularization at color-Doppler were found. No pathological lymph nodes were found in ipsilateral supra and subclavicular lymph node stations as well as in lymph nodes contralateral to the site of vaccine injection.

US follow-up performed 4 weeks later showed stable lymph node size with restored fatty hilum as well as reduced cortical thickness and vascularization (Fig. 6).

**Discussion**

As the world approached the large-scale COVID-19 vaccine distribution with several million doses of mRNA COVID-19 vaccines first rapidly rolled out to the population, many local and systemic reactions were observed after injections, frequently after the second dose. While axillary adenopathy has been rarely reported for other vaccinations such as BCG, influenza and human papilloma vaccinations, it seems to be a very common reaction after COVID-19 vaccine [6–8].
Hyperplastic axillary nodes that can indeed be seen after COVID-19 vaccination showing heterogeneous findings in morphology including size, shape and echogenicity with no clearly described patterns. According to the Centers for Disease Control and Prevention, more than 11% of other vaccine cases lead to swollen lymph nodes after one dose, rising to 16% after the second [9]. Such symptoms usually appear 2–4 days after the vaccine and decline after 2 weeks. Based on our experience, solitary and multiple axillary, supra and subclavicular lymph nodes can be found abnormal at US examination performed after both first and second dose of Pfizer-BioNTech vaccine, ipsilaterally to the site of injection, in young healthy subjects. No pathological cervical lymph nodes were found in our case series. Five out of six subjects presented clinical symptoms, such as ipsilateral armpit pain, palpable axillary lump, fatigue and fever. However, pathological findings can also be found in asymptomatic subjects, as occurred in the remaining sixth case. Imaging features consisted of hypoechoic round or oval nodes as well as lymph node with preserved fatty hilum, but increased (> 3 mm) diffuse or asymmetric cortical thickness, thus mimicking nodal metastases. Vascular signal was mainly found to be increased, localized in both hilar and cortical regions. Shear-wave elastography showed a soft cortical consistence in all cases, with quantitative values comprised between 3.4 and 38 kPa. All values were inferior to the reported threshold for malignancy, 42 kPa, which showed a negative predictive value of 93.2 in a recent study [10]. Although this is not the first case series reporting US features of COVID-19 vaccine-related lymphadenopathies, to the best of our knowledge this is the first one focused on US findings also providing shear-wave sonoelastography data that were not provided in any of the previous experiences [11]. As for B-mode and color-Doppler imaging, cortical thickening and increased vascularity are confirmed as the key imaging features.

Based on the described findings, it is also possible to affirm that, differently from what has been described for other vaccines, such pathological findings can persist even after 4 weeks. Considering the widespread use of US and its main role for lymph-node evaluation [12], it is essential for every radiologist to know how axillary, supra and subclavicular lymph nodes can appear at US after mRNA COVID-19 vaccination prior to assess potentially unnecessary and costly lymph node biopsies. In this context, further data are still necessary to establish the appropriate timeline of follow-up examinations, especially in oncologic patients. Mehta and colleagues proposed a follow-up range between 4 and 12 weeks, which might be appropriate [13]. However, with proper knowledge of US features and patient vaccination history, it has been hypothesized that follow-up could be unnecessary [11]. Interestingly, the recent recommendations suggest that imaging should be performed before vaccination whenever possible while nonurgent exams should be postponed for at least 6 weeks after the administration of the final dose [3]. However, re-scheduling diagnostic procedures might not be always easy and/or possible. Thus, radiologists should be aware of the incidence and significance of this side effect as well as be able to correctly assess its key imaging features. In the absence of a clear timing, a possibility could be to perform a US examination in selected cases before vaccine administration to rule out the presence of a pre-existing lymphadenopathy.

Conclusion

In conclusion, mRNA-based vaccines can lead to the occurrence of pathological lymph nodes that can be indistinguishable from the metastatic ones at US. Although B-mode and color-Doppler features frankly mimic those of metastatic lymph nodes, quantitative parameters derived from shear-wave sonoelastography may be effective for the differential diagnosis. Future studies on larger cohorts of subjects should be conducted to further confirm our findings.

Author contributions DD and FL: Data collection and management, manuscript Writing; RV: Project development, data analysis, manuscript Editing; SA: Manuscript writing and Editing, Literature Search and Review; MS: Manuscript writing and Editing, Content planning; BA: Manuscript Editing, Content planning.

Funding Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement. This study received no funding.

Availability of data and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. MATERIAL and data are all available.

Code availability Not applicable.

Declarations

Conflict of interest All the authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The data obtained in this study did not interfere with course of treatment for patients included.

Humans and animal rights Not applicable.
Additional consent for publication was obtained from all individual participants included in the study.

Consent to participate Additional consent to participate was obtained from all individual participants included in the study.

Consent for publication Additional consent for publication was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD (2021) BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. https://doi.org/10.1056/NEJMoa2101765 (PMID: 33626250; PMCID: PMC7944975)

2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, French RW Jr, Hammit LL, Türeci Ö, Nell H, Schaefer A, Unal S, Tresnam DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoaa2102577 (PMID: 33301246; PMCID: PMC6695226)

3. Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Illica AT, Mayer EL, Shinagare AB, Yeh R, Mayerhoefer ME, Hricak H, Vargas HA (2021) Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. Radiology 24:210436. https://doi.org/10.1148/radiol.2021210436

4. Özütemiz C, Krystosek LA, Church AL, Chauhan A, Ellermann JM, Domingo-Musibay E, Steinberger D (2021) Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients. Radiology 24:210275. https://doi.org/10.1148/radiol.2021210275

5. Ahn RW, Mootz AR, Brewington CC, Abbara S (2021) Axillary lymphadenopathy after mRNA COVID-19 vaccination. Radiol Cardiothorac Imaging 3(1):e210008. https://doi.org/10.1148/ryct.20212100008 (PMID:33778667 PMCID:PMC7861140)

6. Newfeld L, Naschitz JE, Yeshurun D (1990) BCG-induced axillary lymphadenitis in the adult. Harefuah 119(7–8):199–200 (Hebrew. PMID: 2258094)

7. Studdiford J, Lamb K, Horvath K, Altshuler M, Stonehouse A (2008) Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination. Pharmacotherapy 28(9):1194–1197. https://doi.org/10.1592/phco.28.9.1194 (PMID: 18752390)

8. Shirone N, Shinkai T, Yamane T, Uto F, Yoshimura H, Tamai H, Imai T, Inoue M, Kitano S, Kichikawa K, Hasegawa M (2012) Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination. Ann Nucl Med 26(3):248–252. https://doi.org/10.1007/s12149-011-0568-x (PMID: 22271546)

9. Centers for Disease Control and Prevention (2021) Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html. Accessed 16 Jan 2021

10. Lo WC, Hsu WL, Wang CT, Cheng PW, Liao LJ (2019) Incorporation of shear wave elastography into a prediction model in the assessment of cervical lymph nodes. PLoS ONE 14(8):e0221062. https://doi.org/10.1371/journal.pone.0221062 (PMID:3145610 ;PMCID:PMC6695226)

11. Mortazavi S (2021) Coronavirus disease (COVID-19) vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women. AJR Am J Roentgenol. https://doi.org/10.2214/AJR.21.25651 (PMID: 33486146)

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.